Participants in Part 1 were from "Site 1". Participants received a single oral dose of the NOMAC-E2 fixed-dose combination commercial tablet (2.5 mg NOMAC/1.5 mg E2) on the first day of Period 1 and Period 3 Participants received a single oral dose of the NOMAC-E2 fixed-dose combination tablet (2.5 mg NOMAC/1.5 mg E2) from the Phase 3 clinical trial program ("Batch A") on the first day of Period 2 and Period 4. Study Results Participant Flow Recruitment Details More Information PublicationsNone provided. Study Documents (Full-Text)None provided. Recent history of medication use of certain medications specified in the protocol. Smoked more than 10 cigarettes or equivalent tobacco use per day Ĭontraindications for the use of contraceptive steroids Study (eg, laboratory or clinical evaluation) within 30 days of baseline History of alcohol or drug abuse in the past 2 years Ĭurrent participation in another clinical study or had participated in a clinical History of any infectious disease that affected the subject's ability to participate Healthy postmenopausal females between the ages of 45 and 70 years, inclusive, havingĪ Body Mass Index (BMI) between 18 and 32, inclusive įree of any clinically significant disease that would interfere with the studyĪny surgical or medical condition which might significantly alter the absorption,ĭistribution, metabolism or excretion of any drug
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |